Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration ; day:7 ; month:5 ; year:2024 ; pages:1-6
The journal of prevention of Alzheimer's disease ; (7.5.2024), 1-6

Creator: Ozawa, T.
Franguridi, G.
Mattke, Soeren

Contributor: SpringerLink (Online service)

DOI: 10.14283/jpad.2024.81

URN: urn:nbn:de:101:1-2407151352499.081219411433

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:56 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Ozawa, T.
Franguridi, G.
Mattke, Soeren
SpringerLink (Online service)

Other Objects (12)

Disease-modifying treatments in Alzheimer’s disease

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy

Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review

Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease

Disease-modifying treatments in Alzheimer’s disease

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy

Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review

Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease

Disease-modifying treatments in Alzheimer’s disease

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy

Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review

Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Disease-modifying treatments in Alzheimer’s disease

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy

Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review

Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease

Disease-modifying treatments in Alzheimer’s disease

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy

Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review

Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease

Disease-modifying treatments in Alzheimer’s disease

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy

Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review

Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease

Related objects

Reset password